FLT:ASXFlight Centre Travel Group Limited Analysis
Data as of 2026-03-15 - not real-time
A$11.32
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Flight Centre is trading at AU$11.32, well below its 20‑day (AU$12.72), 50‑day (AU$14.21) and 200‑day (AU$13.16) moving averages and just above the identified support level of AU$11.25. The RSI of 25.4 signals oversold conditions, while the MACD remains bearish, suggesting short‑term pressure despite an increasing volume trend. Volatility is elevated at over 50% on a 30‑day basis and beta is modest (~0.9), indicating the stock moves with the market but can swing sharply. On the fundamentals side, the company posted 6.1% revenue growth and a forward EPS of AU$1.27, compressing the forward P/E to under 9x. The DCF‑derived fair value of AU$17.67 implies a 52% upside versus the current price, and analysts (14) collectively rate the stock as a Buy. A dividend yield of 3.62% with an 80% payout ratio is supported by positive operating and free cash flow, though the balance sheet shows a high debt‑to‑equity of 108%. Recent commentary from TipRanks and The Motley Fool highlights the attractive dividend and buy rating, reinforcing the valuation case. Overall, the stock appears significantly undervalued with strong upside potential, but the technical picture remains bearish and the high leverage adds a layer of risk.
Given the substantial valuation gap, improving earnings outlook, and solid dividend profile, medium‑ to long‑term investors may find FLT compelling, while short‑term participants should monitor support levels and volatility. The combination of a cyclical travel sector and global exposure introduces sector and geographic risk, yet the current pricing offers a margin of safety for patient investors.
Given the substantial valuation gap, improving earnings outlook, and solid dividend profile, medium‑ to long‑term investors may find FLT compelling, while short‑term participants should monitor support levels and volatility. The combination of a cyclical travel sector and global exposure introduces sector and geographic risk, yet the current pricing offers a margin of safety for patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support
- Oversold RSI indicating potential bounce
- High volatility and bearish MACD
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggesting >50% upside
- Forward earnings growth compressing P/E to ~9x
- Attractive dividend yield with sustainable cash flow
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Significant valuation discount to intrinsic value
- Long‑term revenue growth and sector recovery
- Consistent dividend policy and analyst buy consensus
Key Metrics & Analysis
Financial Health
Revenue Growth6.10%
Profit Margin3.82%
P/E Ratio22.6
ROE9.02%
ROA3.33%
Debt/Equity108.65
P/B Ratio2.0
Op. Cash FlowA$244.3M
Free Cash FlowA$255.8M
Technical Analysis
TrendNeutral
RSI25.4
SupportA$11.25
ResistanceA$14.28
MA 20A$12.72
MA 50A$14.21
MA 200A$13.16
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair ValueA$17.67
Target PriceA$17.27
Upside/Downside52.55%
GradeUndervalued
TypeBlend
Dividend Yield3.62%
Risk Assessment
Beta0.91
Volatility50.74%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.